Cogent Biosciences Inc
Change company Symbol lookup
Select an option...
COGT Cogent Biosciences Inc
VONG Vanguard Russell 1000 Growth Index Fund ETF Shares
DPRO Draganfly Inc
BCIM abrdn Bloomberg Industrial Metals Strategy K-1 Free ETF
BCH Banco de Chile
BCEL Atreca Inc
BCDF Horizon Kinetics Blockchain Development ETF
BCDA BioCardia Inc
BCBP BCB Bancorp Inc
BCAT Black Rock Capital Allocation Trust
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Cogent Biosciences, Inc. is a biotechnology company that is focused on developing precision therapies for genetically defined diseases. The Company’s most advanced clinical program, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. The Company has initiated APEX, a Phase II clinical study of bezuclastinib in patients with AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib. It also initiated Peak, a randomized, open-label, global Phase III clinical trial.

Closing Price
$14.16
Day's Change
-0.45 (-3.08%)
Bid
--
Ask
--
B/A Size
--
Day's High
14.53
Day's Low
13.83
Volume
(Average)
Volume:
1,083,158

10-day average volume:
1,054,559
1,083,158

CATCHMARK TIMBER TRUST ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of CTT and Encourages Investors to Contact the Firm

12:28 pm ET June 2, 2022 (Globe Newswire) Print

EQNX::TICKER_START (NYSE:CTT),(NASDAQ:PCH), EQNX::TICKER_END Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of CatchMark Timber Trust, Inc. (NYSE: CTT) breached their fiduciary duties or violated the federal securities laws in connection with the company's merger with PotlatchDeltic Corporation (NASDAQ: PCH).

Click here to learn more and participate in the action.

On May 31, 2022, CatchMark announced that it had entered into an agreement to merge with PotlatchDeltic in a deal valued at approximately $5 billion. Pursuant to the merger agreement, CatchMark stockholders will receive 0.23 shares of PotlatchDeltic common stock for each share of CatchMark common stock owned. The deal is scheduled to close in the second half of 2022.

Bragar Eagel & Squire is concerned that CatchMark's board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for CatchMark's stockholders.

If you own shares of CatchMark and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato by email at mergers@bespc.com or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.

Melissa Fortunato, Esq.

mergers@bespc.com

www.bespc.com

https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg

https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg

comtex tracking

COMTEX_408107769/2010/2022-06-02T12:28:20

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.